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GLP-1 analogues 4 $1,295,681
SGLT-2 inhibitors 4 $1,227,029
DPP-4 inhibitors 5 $635,773





Background: Growth in pharmaceutical expenditures for diabetes outpaced 
growth in diabetes prevalence. Prescribers accepting gifts and meals from 
pharmaceutical companies have been linked with higher prescription rates and 
costs.1 Pharmaceutical marketing to these prescribers and patients often 
promotes newer, more expensive drugs, such as the GLP-1 analogues and SGL-2 
inhibitors. These two drug classes are more expensive but no more effective 
than metformin, the recommended first-line treatment for diabetes, and the 
oldest and cheapest available treatment. 2 We investigated how cost of diabetes 
treatment was affected by marketing practices in the District of Columbia.
Methods: The AccessRx program in DC requires pharmaceutical companies to 
report gifts given to healthcare providers, drug advertising expenses, and the 
salaries for staff engaged in promotional activities (“detailing expenses”). We 
combined data from AccessRx and the federal Open Payments system to 
estimate promotional payments. We used Medicaid drug utilization data to 
examine spending for diabetes treatment.
Results: In 2014, DC Medicaid spent more than $17.1 million on pharmaceutical 
treatments for diabetes. We estimated that ten companies spent $3.8 million in 
detailing expenses to market diabetes drugs in 2014. SGLT-2 inhibitors and GLP-1 
analogues had the highest estimated detailing expenses, each totaling more 
than $1.2 million. From 2014 to 2015, DC Medicaid spending for Victoza 
(liraglutide), a GLP-1 analogue, increased 51% (from $183,873 to $362,230) and 
Invokana (canagliflozin), a SGLT-2 inhibitor, increased 213% (from $8,933 to 
$27,958). 
Conclusions: Pharmaceutical promotion drives unnecessary use of newer, more 
expensive medications. The District of Columbia should provide education on 
rational prescribing for diabetes treatment (including diet and exercise).
Abstract Analysis of DC Medicaid Spending
In 2014, one in eleven (9.1%) of DC residents had diabetes. Diabetes was the ninth leading cause 
of hospitalization in DC, with 1,572 visits. Diabetes was the fifth leading cause of death in DC, 
killing more people than lower respiratory diseases, Alzheimer’s disease, HIV/AIDS, or homicides.3
The District of Columbia Medicaid prescription drug program cost $153 million in 2014, of which 
Medicaid reimbursed $151.9 million. Drugs to treat diabetes made up more than 10% of all DC 
Medicaid drug spending. Between 2010 and 2014, DC Medicaid spending on diabetes drugs 













Payments to Physicians Associated with Diabetes Drugs 
across Medical Specialties
Promotion of Diabetes Drugs
In 2014, pharmaceutical and device manufacturers reported a total of 
$91.1 million for gift, advertising, and aggregate (detailing) expenses in 
the District of Columbia.5
We identified 50 diabetes drugs (42 branded and 8 generic drugs). 
According to data from Open Payments, physicians accepted more than 
$360,000 worth of gifts related to diabetes medication from 
pharmaceutical and device manufacturers.
Invokana (canagliflozin), a SGLT-2 inhibitor, was the diabetes drug with 
the most associated payments with $154,000. Bydureon (exenatide) and 
Victoza (liraglutide), both GLP-1 analogues, were associated with gifts to 
physicians totaling $65,191 and $44,659 respectively.
Funding for this research came from the District of Columbia Department of 
Health, Health Regulation and Licensing Administration. 






Estimating Diabetes Detailing Expenses




GLP-1 analogues and SGLT-2 inhibitors are both relatively new classes of diabetes drugs, and both 
classes had relatively low numbers of prescriptions reimbursed by DC Medicaid in 2014. GLP-1 
analogues had the highest costs per prescription, ranging from $404 - $489. SGLT-2 inhibitors also 
had high costs per prescriptions, ranging from $271 - $303. These newer drug classes show modest 
benefits but are far more expensive than the older, more efficacious diabetes drug metformin.2
Attributed Detailing Formula
Summary of Attributed Detailing
Cost of Diabetes Drugs to DC Medicaid
To estimate the amount spent on detailing  for each diabetes drug, we developed a methodology to combine 
information from Open Payments and AccessRx. Drugs were grouped by class in order to maintain the  
confidentiality of proprietary data. The attributed aggregate detailing amount could be a marker for how extensively 
specific drugs are being marketed in the District. 
We estimate that these ten companies spent about $3.8 million in salary for sales staff to promote diabetes drugs in 
the District of Columbia. The newly approved SGLT-2 inhibitor and GLP-1 analogue drug classes had the highest 
estimated detailing amounts, totaling more than $1.2 million each. We predicted that high expenditures for 
promoting these classes in 2014 would precede an increase in the number of prescriptions reimbursed by DC 
Medicaid  for these two classes of antidiabetics in 2015. 
As follow-up to this analysis, we found that spending for some SGLT-2 inhibitors and GLP-1 analogues had increased. 
From 2014 to 2015, DC Medicaid spending for Victoza (liraglutide), a GLP-1 analogue, increased 51% (from $183,873 
to $362,230) and Invokana (canagliflozin), a SGLT-2 inhibitor, increased 213% (from $8,933 to $27,958). 
While our research shows some connection between marketing and increased public expenditures on drugs, further 
research into the effects of pharmaceutical marketing on prescribing choices and its effect on public programs like 
Medicaid is needed.
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